Annual Meeting Offers Industry Education and Entertainment
|
By LabMedica International staff writers Posted on 08 Jun 2017 |
|
Image: Genome editing with CRISPR-Cas9 offers the potential to treat human genetic disease (Photo courtesy of Feng Zhang).
Registration has opened for the 2017 annual meeting of the American Association of Clinical Chemistry, which has promised novel and interesting sessions that will highlight emerging science, practices, and technologies across the spectrum of clinical laboratory medicine.
The 69th AACC Annual Scientific Meeting & Clinical Lab Expo will be held in San Diego, CA, USA, from July 30 to August 3. In addition to a strong lineup of plenary speakers, which will be headed by Dr. Jennifer Doudna, professor of chemistry and molecular and cell biology at the University of California, Berkeley (USA) – who will be speaking about advances in CRISPR/Cas9 gene editing technology – there will be a mock courtroom session and two quiz games.
The mock trial session will illustrate the importance of expert witness testimony in resolving litigation associated with toxicology and clinical laboratories. One quiz game will pit the AACC leadership against members of the Society for Young Clinical Laboratorians. The teams will contest various laboratory medicine topics such as oncology and cardiovascular biomarkers, molecular testing, point-of-care testing, therapeutic drug management/toxicology, and over-utilized or outdated tests.
The second quiz game will engage the audience on topics addressing Zika virus, mass spectrometry, antimicrobial resistance, and other infectious disease issues and diagnostic solutions.
A highlight of the conference will be the Qualcomm Tricorder XPRIZE special session. Two participants in this $10 million global competition to develop devices capable of diagnosing at least 13 health conditions and continuously monitoring five vital signs, all with a consumer-friendly interface and weighing no more than five pounds (2.27 kilograms), will present their innovations.
Related Links:
AACC Annual Scientific Meeting & Clinical Lab Expo
University of California, Berkeley
The 69th AACC Annual Scientific Meeting & Clinical Lab Expo will be held in San Diego, CA, USA, from July 30 to August 3. In addition to a strong lineup of plenary speakers, which will be headed by Dr. Jennifer Doudna, professor of chemistry and molecular and cell biology at the University of California, Berkeley (USA) – who will be speaking about advances in CRISPR/Cas9 gene editing technology – there will be a mock courtroom session and two quiz games.
The mock trial session will illustrate the importance of expert witness testimony in resolving litigation associated with toxicology and clinical laboratories. One quiz game will pit the AACC leadership against members of the Society for Young Clinical Laboratorians. The teams will contest various laboratory medicine topics such as oncology and cardiovascular biomarkers, molecular testing, point-of-care testing, therapeutic drug management/toxicology, and over-utilized or outdated tests.
The second quiz game will engage the audience on topics addressing Zika virus, mass spectrometry, antimicrobial resistance, and other infectious disease issues and diagnostic solutions.
A highlight of the conference will be the Qualcomm Tricorder XPRIZE special session. Two participants in this $10 million global competition to develop devices capable of diagnosing at least 13 health conditions and continuously monitoring five vital signs, all with a consumer-friendly interface and weighing no more than five pounds (2.27 kilograms), will present their innovations.
Related Links:
AACC Annual Scientific Meeting & Clinical Lab Expo
University of California, Berkeley
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Automatic CLIA Analyzer
Shine i6000
Latest AACC 2017 News
- Siemens Healthineers Showcases Atellica Solution at AACC 2017
- Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo
- Combating Infectious Diseases Key Focus of AACC
- World's First Fully Integrated LC-MS/MS Clinical Analyzer Unveiled
- Clinical Chemistry Analyzer Provides DAU Screening
- Diatron Displays New Hematology Analyzer at UAE Congress
- Microscan Demonstrates Advanced Technology at Scientific Meeting
- AACC Middle East to Be Held in Abu Dhabi
- AACC 2017 Focus on CRISPR and Futuristic Testing Devices
- Opioid Drug Abuse Testing Key Topic at Congress
- Keynote Address to Focus on CRISPR/Cas9 Gene Editing
- Winner of Qualcomm Tricorder XPrize Unveiled at AACC
Channels
Clinical Chemistry
view channel
Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read more
Molecular Diagnostics
view channel
Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
Lynch syndrome is a hereditary condition that increases risk for colorectal and endometrial cancers and often results in earlier-onset disease. Clinicians need better ways to stratify asymptomatic carriers... Read more
Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive condition characterized by obstructed pulmonary blood flow and strain on the right heart, with half of patients dying within five years of diagnosis.... Read more
Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
Racial survival disparities in early-stage breast cancer remain a persistent clinical concern in the United States, with Black women experiencing higher mortality despite similar treatments.... Read more
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read more
Immunology
view channel
Combined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read more
Pathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more_image.png "Image: Through neoadjuvant therapy combining chemotherapy with immune checkpoint inhibitors (ICI) for 46 LAGC patients and single-cell transcriptome sequencing, researchers found that tumor cells in the treatment-sensitive group specifically upregulated MHC-II (tumor-specific major histocompatibility complex class II, tsMHC-II) molecules (photo courtesy of Science China Press)")
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read more
Technology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
Global Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more
